---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-007147"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:27:24.643419+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events

## Summary
- Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.
- In vivo EAE model: HDFs suppressed Th17, expanded Tregs, stimulated remyelination, outperformed adipose/bone marrow MSCs.
- Company designing phase II trial to test various HDF spheroid doses and multiple-dose treatments over 18 months.
- Presentation at ACTRIMS Forum 2024 on Feb 29 in West Palm Beach, FL (poster P341).

## SEC filing metadata
- accession: 0001493152-24-007147
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224007147/0001493152-24-007147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224007147/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-007147
- JSON: https://secwatch.observer/filing/0001493152-24-007147.json
- Plain text: https://secwatch.observer/filing/0001493152-24-007147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.